Hyaluronan/Autologous bone marrow mononuclear cell

N/A

Report date: 2023/01/01 09:47:44

Base Information

Drug NameHyaluronan/Autologous bone marrow mononuclear cell

Drug Alias NameRV-P1501

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Leukocyte cell therapy > Monocyte cell therapyCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derived

Mechanisms of ActionCell replacements

TargetsNot applicable

Therapy Area/IndicationsPeripheral arterial occlusive disorders

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsYes Autologous bone marrow mononuclear cells (Oregon Health and Science University)

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesAcademia Sinica

China Registration ClassN/A

Develop Information

Active CompaniesAcademia Sinica

Inactive CompaniesN/A

Active IndicationsPeripheral arterial occlusive disorders

Inactive IndicationsN/A

Other Information

ATC CodeN/A